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Mitoxantrone and Analogues Bind 
and Stabilize i-Motif Forming DNA 
Sequences
Elisé P. Wright1, Henry A. Day1, Ali M. Ibrahim2, Jeethendra Kumar2, Leo J. E. Boswell1, 
Camille Huguin1, Clare E. M. Stevenson3, Klaus Pors2 & Zoë A. E. Waller1,4
There are hundreds of ligands which can interact with G-quadruplex DNA, yet very few which target 
i-motif. To appreciate an understanding between the dynamics between these structures and how 
they can be affected by intervention with small molecule ligands, more i-motif binding compounds 
are required. Herein we describe how the drug mitoxantrone can bind, induce folding of and stabilise 
i-motif forming DNA sequences, even at physiological pH. Additionally, mitoxantrone was found 
to bind i-motif forming sequences preferentially over double helical DNA. We also describe the 
stabilisation properties of analogues of mitoxantrone. This offers a new family of ligands with potential 
for use in experiments into the structure and function of i-motif forming DNA sequences.
i-Motifs are quadruplex DNA secondary structures formed from cytosine-rich sequences and stabilised by inter-
calated, hemi-protonated cytosine-cytosine base pairs1. Putative i-motif forming sequences occur throughout 
the genome, typically opposing regions which can form G-quadruplexes; they are particularly enriched in gene 
promoters2–4, suggestive of their involvement in gene transcription. Evidence of the effects and potential roles of 
i-motifs in biology are limited by previous assumptions that i-motifs always require acidic conditions to form and 
the subsequent lack of chemical tools and ligands which can be used in their study5. Nevertheless, stabilisation of 
the human telomeric i-motif with single walled carbon nanotubes has been shown to inhibit telomerase activity 
and interfere with telomere biology6,7. Furthermore, stabilisation of a promoter i-motif in the bcl-2 oncogene by 
steroidal-based compounds resulted in a subsequent increase in gene expression8,9. In contrast to the hundreds 
of G-quadruplex binding ligands, there are very few i-motif binding compounds reported in the literature5. To 
improve the development of understanding into the potential roles of i-motif structures in the genome, a more 
diverse tool-box of potential compounds is required. Herein we describe a new family of i-motif binding ligands 
which can preferentially stabilise i-motif forming DNA sequences, even at physiological pH.
Results and Discussion
Given the scant literature surrounding i-motif binding compounds, we decided to use a screening strategy to 
identify any potential leads. We used a medium throughput Fӧ rster resonance energy transfer (FRET)-based 
DNA melting screen10 of a 960 compound library from MicroSource against the i-motif forming sequence from 
the human telomere (hTeloCFRET, 5′ -FAM-[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-TAMRA-3′ ) at pH 5.5, 
where this sequence is mainly in a folded conformation. The MicroSource library houses a wide range of known 
drugs, natural products and biologically active compounds. From the initial screen (Fig. S1) we identified 
mitoxantrone as a suitable lead compound from which to start further binding studies. Mitoxantrone is a known 
type 2 topoisomerase inhibitor11 and a drug used in the treatment of leukemia, non-Hodgkin’s lymphoma, met-
astatic breast cancer12 and to slow the progression of multiple sclerosis13. Anthraquinone compounds similar 
to mitoxantrone, have also been found to inhibit telomerase activity by stabilisation of the G-quadruplex14–16. 
Supporting circular dichroism (CD) experiments indicated that mitoxantrone interacts with i-motif DNA 
(Fig. S9) so we used surface plasmon resonance (SPR) to measure equilibrium binding between mitox-
antrone and i-motif DNA. SPR experiments were performed using three different immobilised DNA targets: 
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hTeloCBiotin (5′ -biotin-[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-3′ ), c-mycBiotin (5′ -biotin-[CCT-TCC
-CCA-CCC-TCC-CCA-CCC-TCC-CCA]-3′ and also double stranded DNA (DSbiotin) for comparison, which 
comprised the ODN d(biotin-[GGC-ATA-GTG-CGT-GGG-CGT-TAG-C]) hybridized with its complementary 
strand. Example sensorgrams and fittings are given in Fig. 1.
The SPR results showed that mitoxantrone has moderate affinity for the i-motif at pH 5.5, with dissociation 
constants in the low micromolar range. The affinity for hTeloC and c-myc were found to be the same within error 
(Kd = 12 ± 3 and 12 ± 3 μ M for hTeloC and c-myc respectively). However, the affinity for double stranded DNA 
was found to be significantly weaker and because of this could not be as accurately determined using the same 
range of concentrations. Nevertheless, the dissociation constant was found to be approximately five times lower 
than i-motif (approximate Kd = 71 ± 22 μ M). This indicates a definite preference towards i-motif structures in the 
equilibrium binding studies. These affinities are of a similar magnitude to existing i-motif ligands such as the phe-
nanthrolines (4–8 μ M at pH 5.5)17 but slightly better than the previously described terbium complexes (22–30 μ M 
at pH 5.5)18 and the cationic porphyrin TmPyP4 (45 μ M at pH 4.5)19.
To investigate how mitoxantrone interacts with different types of DNA, further FRET-based melting exper-
iments were performed across a wider range of conditions and types of DNA secondary structure. DNA melting 
experiments provides a measure of the ligand-induced stabilisation of a folded structure. FRET melting exper-
iments have advantages over other DNA-based melting experiments in that screening of a large range of condi-
tions/ligand concentrations is possible; lower concentrations are required and it avoids the problem that many 
ligands absorb in the same region as DNA, which may interfere with the absorbance or ellipticity signal result-
ing from complex dissociation20. However, the technique can give rise to experimental artefacts from inher-
ently fluorescent ligands and compounds which interact with the fluorophores rather than the DNA itself21. The 
Figure 1. Example sensorgrams (left) and fittings (right) for mitoxantrone with hTeloCbiotin (top) c-mycbiotin 
(middle) and DSbiotin (bottom) in pH 5.5 10 mM sodium cacodylate supplemented with 100 mM NaCl, 
0.05% tween-20 and 5% DMSO. Sensorgrams are double referenced and solvent corrected.
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fluorophores can also alter the folding properties of the DNA22. The technique is used widely for assessment of 
DNA-ligand interactions and we chose to mimic the conditions used by others studying i-motif ligands6,23. The 
FRET melting experiments were performed using mitoxantrone and a range of dual-labelled oligonucleotides: 
i-motif forming sequences from the human telomere (hTeloCFRET) and the c-myc oncogene (c-mycFRET, 5′ -FAM-
[TCC-CCA-CCT-TCC-CCA-CCC-TCC-CCA-CCC-TCC-CCA]-TAMRA-3′ ); G-quadruplex forming sequence 
from the human telomere (hTeloGFRET, 5′ -FAM-[GGG-TTA-GGG-TTA-GGG-TTA-GGG]-TAMRA-3′ ) and a 
duplex forming sequence (DSFRET, 5′ -FAM-[TAT-AGC-TAT-A-HEG(18)-TAT-AGC-TAT-A]-TAMRA-3′ ). To 
support the previous experiments with i-motif, which were performed at acidic pH (pH 5.5), we also performed 
experiments with i-motif forming sequences at their respective transitional pHs (pHT: 6 for hTeloC and 6.6 for 
c-myc)24,25, the pH at which the DNA structure is 50% folded. Experiments at pHT allow studies at a higher pH, 
where part of the population in solution remains folded into i-motif, but is closer to physiological pH. Given the 
Kd of mitoxantrone with i-motif was 12 μ M, initially 10 μ M ligand concentration was used across all the experi-
ments and the buffer and cation concentration was also kept constant (10 mM sodium cacodylate, 100 mM NaCl). 
On addition of 10 μ M mitoxantrone to the DNA, the change in melting temperature (∆ Tm) for i-motif DNA at 
pH 5.5 was high (hTeloC ∆ Tm = + 34 °C and c-myc = + 31 °C). However, when the experiments were performed 
at the transitional pHs, the stabilisation was even higher for both hTeloC (∆ Tm = + 42 °C at pH 6) and c-myc 
(∆ Tm = + 38 °C at pH 6.6). Mitoxantrone was also found stabilise double helical DNA, but to a much lesser 
degree (∆ Tm = + 6.4 °C), which is consistent with the Kd values obtained by SPR. It is unsurprising that mitox-
antrone was also found to stabilise the G-quadruplex forming sequence from the human telomere (hTeloG, 
∆Tm = + 16 °C), but again, the stabilisation was not as high as that for the i-motif forming sequences at the same 
concentration.
Although at physiological pH the i-motif forming sequences from the human telomere and c-myc reside in a 
predominantly unfolded conformation24,25, we were encouraged by the positive results in the experiments per-
formed at transitional pH. Performing analogous melting experiments at pH 7.4 gave a stabilisation temperatures 
of + 27 °C for hTeloC and + 29 °C for c-myc, indicating that mitoxantrone can induce folding of hTeloC and 
c-myc in the absence of the acidic conditions typically required for these particular sequences. Further experi-
ments across a wider concentration range with hTeloC shows a dose-dependent increase in folded DNA structure 
(Fig. 2a). At pH 7.4, hTeloC is unfolded at 25 °C, indicated in the FRET experiments by high fluorescence signal 
across the whole temperature range (Tm < 25 °C). At the lowest concentration of mitoxantrone (0.2 μ M) there 
is a slight reduction in fluorescence signal at the start of the melting experiment (25 °C), indicating part of the 
DNA population is folded. This reduction increases in a concentration-dependent manner until 5 μ M, where the 
fluorescence is fully quenched, indicating predominantly folded populations at 25 °C. Higher concentrations of 
mitoxantrone gave further increases in melting temperature. Stabilisation temperatures were calculated assum-
ing a Tm of 25 °C in the absence of any ligand, i.e. the minimum possible Tm under the conditions used in this 
experiment. A concentration versus Tm plot is shown in Fig. 2b. Analogous experiments with c-myc showed 
similar behavior (Fig. S2). Further example melting curves and concentration versus Tm plots for all the DNA 
structures (and conditions) are also provided in the SI.
Although carboxyl modified single walled carbon nanotubes have been shown to stabilise i-motif forming 
DNA sequences at neutral pH6, to the best of our knowledge, this is not yet documented in the literature for small 
molecule ligands. Nevertheless, mitoxantrone still has some interaction with double helical DNA in both the 
FRET and SPR experiments. To see whether it was possible to gain higher specificity for i-motif over double hel-
ical DNA, we decided to investigate the stabilisation capabilities of analogue compounds. Previous studies using 
analogues of mitoxantrone allowed easy access to a mixture of both known and novel structures26–30. An initial 
Figure 2. (a) Example FRET melting curves for hTeloC (200 nM) with 0, 0.2, 0.5, 1, 2, 5, 7.5, 10 and 20 μ M 
mitoxantrone in pH 7.4 10 mM sodium cacodylate and 100 mM NaCl. (b) Plots of change in DNA melting 
temperature against concentration of mitoxantrone for hTeloC in 10 mM sodium cacodylate at pH 7.4 with 
100 mM, the error bars represent the standard deviation from three experiments.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:39456 | DOI: 10.1038/srep39456
screen of 25 analogues was performed (Fig. S10); selecting ligands which stabilised i-motif, but not double helical 
DNA at the same concentration, gave rise to a subset of ligands 1–5 which were repeated and are reported in Fig. 3.
The advantage that the analogue compounds (1–5) have over mitoxantrone is their reduced ability to sta-
bilise double helical DNA, with Δ Tm values between − 3 and + 2 °C. Furthermore, all of the analogues reported 
in Fig. 2 also have reduced stabilization potential for the human telomeric G-quadruplex (hTeloG) with Δ Tm 
values between + 0.4 and +13 °C, compared to +16 °C for mitoxantrone. For example, 3 does not stabilise 
G-quadruplex DNA at all, with a Δ Tm of + 0.4 °C for G-quadruplex. The same ligand can also stabilise hTeloC 
well (Δ Tm = +17 °C at pH 6), this indicates some preference for i-motif. However, unfortunately this analogue did 
not induce stabilisation of the i-motif forming sequences at pH 7.4.
Further SPR experiments were performed at pH 5.5 to give an indication of the binding properties of the ana-
logue compounds against i-motif and double stranded DNA. These revealed that ligands 1–5 did not bind i-motif 
as well as mitoxantrone at this pH, which is consistent with the overall reduced stabilisation profiles measured at 
pH 5.5. For example the next best compound, ligand 2, had lower affinity for all the structures; the dissociation 
constants for hTeloC and c-myc were found to be the same within error (Kd = 31 ± 5.1 and 34 ± 6.7 μ M for hTeloC 
and c-myc respectively) and the affinity for double stranded DNA was again found to be approximately five times 
lower than i-motif (approximate Kd = 181 μ M) at pH 5.5.
The FRET melting and SPR results indicate that mitoxantrone and the analogues 1–5 could be useful in dif-
ferent studies into i-motif structure and function, with the potential to choose from subtly different ligands which 
have different pH dependent stabilisation profiles. Although the analogues in this study were not found to have 
improved selectivity beyond that of the parent compound mitoxantrone, this does not rule out the possibility that 
further selectivity for i-motif forming sequences over other DNA secondary structures may be obtained with the 
creation of further analogues based around these scaffolds.
When compared to other small molecule i-motif binding ligands in the literature, mitoxantrone and the 
analogues described herein offer preferential stabilisation of i-motif forming sequences and some even at neu-
tral pH. The cholestane derivative IMC-48 (NSC 138948), which binds the BCL-2 i-motif, only has a Δ Tm of + 
1 °C9 and the previously reported terbium18 and ruthenium31 complexes did not stabilise i-motif structures at all. 
BisA, which has been shown to interact with the human telomeric i-motif, has a Δ Tm of + 33 °C, but this was at 
Figure 3. Structures of the anthraquinones and stabilisation potentials (∆Tm) determined by FRET 
melting. Errors represent the standard deviation from three independent experiments. NS indicates where the 
ligand did not induce stabilisation of the DNA.
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pH 6.823. Overall, mitoxantrone and analogues offer a small-molecule scaffold which can both bind i-motif DNA 
and stabilize i-motif forming sequences better than double helical DNA.
Conclusions
Herein we have described for the first time that mitoxantrone is able to both bind and stabilise i-motif forming 
DNA sequences preferentially over double helical DNA. Furthermore, to the best of our knowledge, this is the 
first example of a small molecule which can stabilise i-motif forming DNA sequences at neutral pH, thus the 
compounds described here have potential for use in the study of i-motif DNA structure and function.
Methods
General Experimental. All the oligonucleotides (ODNs) and their fluorescent conjugates were purchased 
from Eurogentec and were HPLC purified. Solid DNA samples were initially dissolved as a stock solution in 
MilliQ water (100 μ M for labelled and 1 mM for unlabeled ODNs); further dilutions were carried out in the 
respective sodium cacodylate buffer. Annealed samples were thermally annealed in a heat block at 95 °C for 
5 minutes and cooled slowly to room temperature overnight. Non-annealed samples had the DNA diluted into 
the respective buffer and were used immediately. The Gen-Plus library from Microsource Discovery Systems 
Inc. consisting of 960 drug standards with approval in Europe, Japan or the USA, supplied as 10 mM solutions in 
DMSO which were diluted to 1 mM in 96 well plates. Mitoxantrone was purchased as the di-hydrochloride salt 
from Molekula. Stock solutions of ligands at 10 mM were made in purified water and/or DMSO and were stored 
at − 20 °C, subsequent dilutions were made in the appropriate buffer.
For the synthesis of the novel anthraquinones (anthracene-9,10-diones), all chemicals were obtained from 
Aldrich (Poole, Dorset), Lancaster (Morecambe, Lancashire) and VWR (Poole, Dorset). All other solvents were 
supplied by VWR. Reagents were used as received. Flash chromatography was carried out on silica gel [Merck 
9385 Kieselgel 60 (230–400 ASTM) supplied by VWR]. Analytical TLC was carried out on 0.25 mm thick alu-
minium plates precoated with Merck Kieselgel F254 silica gel (VWR) and visualised by UV and aqueous alkaline 
potassium permanganate solution. NMR spectra were recorded on Jeol GX270, Jeol AM600 or Bruker DPX400 
spectrometers. Purity of all compounds are ≥ 95% as measured by HPLC (see SI).
FRET Melting Screen. The initial DNA melting screen was performed using a fluorescence resonance 
energy transfer (FRET) DNA melting based assay. The labelled oligonucleotide hTeloCFRET (5′ -FAM-d[TAA- 
CCC-TAA-CCC-TAA-CCC-TAA-CCC]-TAMRA-3′ ; donor fluorophore FAM is 6-carboxyfluorescein; accep-
tor fluorophore TAMRA is 6-carboxytetramethyl-rhodamine) was prepared as a 220 nM solution in 10 mM 
sodium cacodylate buffer at pH 5.5 with 100 mM sodium chloride and then thermally annealed. Strip-tubes 
(QIAgen) were prepared by aliquoting 18 μ L of the annealed DNA, followed by 2 μ L of 1 mM compound library 
solutions. Control samples for each run were prepared with the same quantity of DMSO with the DNA in buffer. 
Fluorescence melting curves were determined in a QIAgen Rotor-Gene Q-series PCR machine, using a total 
reaction volume of 20 μ L. Samples were held at 25 °C for 5 minutes then ramped to 95 °C at increments of 1 °C, 
holding the temperature at each step for 1 minute. Measurements were made with excitation at 470 nm and detec-
tion at 510 nm. DNA melting points were determined using the first derivative of the melting curve, any exper-
iments where the inflection point was not able to be determined (i.e. the transition does not occur before the 
end of the experiment) were defined to have a Tm of > 95 °C. Initial Hits against hTeloC were repeated in 10 mM 
sodium cacodylate buffer at pH 5.5 at both high and low salt concentrations (100 mM and 5 mM NaCl). Further 
FRET melting experiments were performed using 200 nM DNA in 10 mM sodium cacodylate supplemented 
with 100 mM NaCl with the ligand Mitoxantrone (or respective analogue) added. hTeloCFRET and c-MycFRET 
(5′ -FAM-d[TCC-CCA-CCT-TCC-CCA-CCC-TCC-CCA-CCC-TCC-CCA]-TAMRA-3′ ) were tested at their 
respective transitional pHs (6.0 and 6.6), acidic (pH 5.5) and physiological (pH 7.4). hTeloGFRET (5′ -FAM-d
[GGG-TTA-GGG-TTA-GGG-TTA-GGG]-TAMRA-3′ ) and DSFRET FAM-d(TAT-AGC-TAT-A-HEG(18) 
-TAT-AGC-TAT-A)-TAMRA-3′ ) were measured at pH 7.4. Final analysis of the data was carried out using 
QIAgen Rotor-Gene Q-series software and Origin or Excel.
Circular Dichroism. Circular dichroism (CD) spectra were recorded on a Jasco J-810 spectropo-
larimeter using a 1 mm path length quartz cuvette. Human telomeric i-motif (hTeloC, 5′d[TAA- 
CCC-TAA-CCC-TAA-CCC-TAA-CCC]-3′ ) was diluted in a buffer containing 10 mM sodium cacodylate and 
100 mM NaCl at pH 5.5, to achieve a total volume of 200 μ L. The scans were performed at 20 °C over a wave-
length range of 220–400 nm with a scanning speed of 200 nm/min, a response time of 1 s, 0.5 nm pitch and 2 nm 
bandwidth. A blank sample containing only buffer (and, where necessary ligand) was treated in the same manner 
and subtracted from the collected data. Solutions of mitoxantrone were added in small aliquots to the desired 
equivalent proportions using a pipette. The CD spectra represent an average of three scans and are zero corrected 
at 320 nm. Final analysis and processing of the data was performed using Origin.
Surface Plasmon Resonance. SPR experiments were performed using a GE Healthcare Biacore T200 
instrument with a series S streptavidin (SA) coated chip. For immobilization all DNA samples were biotinylated. 
hTeloCBiotin, (5′ -biotin-d[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-3′ ) c-MycBiotin (5′ -biotin-d[CCT-TCC-
CCA-CCC-TCC-CCA-CCC-TCC-CCA]-3′ ) sequences were diluted to 1 μ M in running buffer (10 mM sodium 
cacodylate (pH 5.5), 100 mM NaCl and 0.05% Tween-20) and the Double stranded DNA DSBiotin (5′ -biotin-d
[GGC-ATA-GTG-CGT-GGG-CGT-TAG-C]-3′ ) was annealed with its complimentary strand at 1 μ M in running 
buffer. For immobilization, the chip was first conditioned with three 60 s washes of 1 M NaCl and 50 mM NaOH at 
a flow rate of 10 μ L min−1 to remove any unconjugated streptavidin. The biotinylated oligonucleotides were then 
injected over flow cells 2 (hTeloCBiotin,761.7 RU), 3 (c-MycBiotin, 664.0 RU) and 4 (DSBiotin+ comp, 568.1 RU) with 
flow cell 1 left blank.
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For affinity measurements, the running buffer was identical but had the addition of 5% DMSO. Ligand stocks 
(10 mM in DMSO) were serially diluted with buffer without DMSO to give concentrations of 100, 50, 25, 12.5, 
6.25, 3.125, 1.56, 0.78, 0.39 and 0 μ M in a final composition the same as the running buffer (10 mM sodium caco-
dylate (pH 5.5), 100 mM NaCl, 0.05% Tween-20 and 5% DMSO). It was crucial that all concentrations of ligand 
contained 5% DMSO and in addition solvent correction was performed where 8 solutions with varying amounts 
of DMSO (4.5–5.8%) were also prepared. The solvent correction samples were run at the start and end of the 
experiment and every 30 cycles. Binding experiments were performed using the affinity run wizard in the Biacore 
T200 software at 25 °C and a flow rate of 30 μ L min−1. Prior to sample injection, 1 startup cycle was performed: 
blank injections of buffer followed by 2 regeneration injections of 1 M NaCl. Each concentration of ligand was 
injected for 120 s and the responses in each flow cell were measured. After each injection the chip surface was 
regenerated by two 60 s injections of 1 M NaCl followed by washing with running buffer for 60 s. Each ligand 
concentration was repeated with a second injection to ensure reproducibility. The response data was solvent cor-
rected and double referenced by subtracting the startup cycle and injections of buffer only samples. Non-selective 
binding to the chip surface was accounted for by subtracting the response from the blank flow cell. Resultant sen-
sorgrams were fitted using the average equilibrium response for each concentration and fitted using the affinity fit 
from the Biacore T200 evaluation software v2.0 assuming a 1:1 binding model.
Mitoxantrone Analogues. 1 and 4–5 were made as previously described20–24.
1,5-bis((2-(piperidin-1-yl)ethyl)amino)anthracene-9,10-dione (2). 1,5-dichloroanthracene-9,10-dione (100 mg, 
0.361 mmol) was stirred in 2-(piperidin-1-yl)ethylamine (1 mL) at 100 °C for 24 h before the solution was poured 
into cold brine. The precipitated solid was isolated by filtration and the crude compound was purified by flash 
column chromatography using CH2Cl2:CH3OH (98:2 → 90:10) to yield the title compound 2 (141.3 mg, 85%) as 
a red solid.
1H NMR (400 MHz, CDCl3): δ (ppm) 9.68 (t, J = 4.72 Hz, 2H, Ar-NH ), 7.48 (m, 4H, ArH), 6.89 (d, J = 7,2 
2H, ArH), 3.38 (q, J = 6.2 Hz, 4H, ArNHCH2CH2), 2.62 (t, 4H, J = 6.8 Hz, ArNHCH2CH2), 2.43 (m, 8H, 
NCH2CH2CH2), 1.58 (m, 8H, NCH2CH2CH2), 1.40 (m, 4H, NCH2CH2CH2); 13C NMR (101 MHz, CDCl3): 
δ (ppm) 184.31, 150.17, 135.29, 134.08, 115.34, 113.75, 112.12, 56.49, 53.66, 39.43, 24.91, 23.31; m/z 461 
([M + H]+, 47%); HRMS (m/z): [M+ H]+ calcd for C28H36N4O2, 461.2911; found, 461.2906.
1-((2-(dimethylamino)ethyl)amino)-5-((2-(phenylamino)ethyl)amino)anthracene-9,10-dione (3). The method 
follows that of 2 using 13 (see SI) (25 mg, 0.066 mmol) and N,N-dimethylethane-1,2-diamine (1 mL). The product 
3 was afforded as a red solid (15.6 mg, 55%).
1H NMR (400 MHz, CDCl3): δ (ppm) 9.76 (t, J = 5.0 Hz, 1H, ArNH), 9.70 (t, J = 4.4 Hz, 1H, ArNH), 
7.53 (d, J = 7.6 Hz, 1H, ArH), 7.45 (m, 3H, ArH), 7.13 (t, J = 7.2 Hz, 2H, ArH), 6.91 (d, J = 7.2 Hz, 2H, ArH), 
6.67 (t, J = 7.2 Hz, 1H, ArH), 6.61 (d, J = 8.0 Hz, 2H, ArH), 3.89 (sbr, 1H, CH2NHPh), 3.53 (q, J = 6.0 Hz, 2H, 
NHCH2CH2NHPh), 3.42 (sbr, 2H, NHCH2CH2NHPh), 3.35 (q, J = 6.4 Hz, 2H, NHCH2CH2N), 2.60 (t, J = 6.4 Hz, 
2H, NHCH2CH2N), 2.28 (s, 6H, NCH3); 13C NMR (101 MHz, CDCl3): δ (ppm) 185.74, 185.23, 151.34, 151.25, 
147.60, 136.37, 136.19, 135.30, 135.26, 129.38, 117.89, 116.54, 116.25, 115.38, 114.87, 113.41, 113.08, 113.05, 
58.06, 45.62, 43.11, 42.16, 40.97; m/z 429 ([M+ H]+, 100%); HRMS (m/z): [M+ H]+ calcd for C26H28N4O2, 
429.2285; found, 429.2285.
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